- Home
- MGEE vs LQDA Comparison
MGEE vs LQDA Comparison
Compare MGEE & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGEE | LQDA |
|---|---|---|
| Founded | 1855 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | 2001 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MGEE | LQDA |
|---|---|---|
| Price | $80.80 | $38.52 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $78.00 | $41.00 |
| AVG Volume (30 Days) | 210.7K | ★ 1.0M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | 11.71 | ★ 51.81 |
| EPS | ★ 3.72 | N/A |
| Revenue | N/A | ★ $158,320,000.00 |
| Revenue This Year | $4.02 | $278.87 |
| Revenue Next Year | $2.77 | $57.13 |
| P/E Ratio | $21.80 | ★ N/A |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $72.17 | $11.85 |
| 52 Week High | $93.24 | $46.67 |
Technical Indicators
Market Signals| Indicator | MGEE | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 60.13 | 54.11 |
| Support Level | $77.73 | $31.75 |
| Resistance Level | $80.99 | $39.19 |
| Average True Range (ATR) | 1.64 | 1.93 |
| MACD | 0.65 | 0.29 |
| Stochastic Oscillator | 80.05 | 58.78 |
Price Performance
Historical ComparisonAbout MGEE MGE Energy Inc
MGE Energy provides electric service to 170,000 customers and natural gas service to 180,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.